Filing Flows › Embecta (EMBC) › Q3 FY25
Embecta (EMBC) Q3 FY25 earnings results (third quarter fiscal 2025)
10-Q filed Aug 8, 2025
Embecta (EMBC) reported revenue of $296M for the third quarter fiscal 2025 (Q3 FY25), +8% from a year earlier and +14% from the quarter before. Operating margin was 31.8%, net earnings $45.5M (15.4% of revenue).
Embecta, Q3 FY25: revenue $296M (+8% year over year), operating margin 31.8%, net earnings $45.5M, operating cash flow $81.2M. The chart follows the revenue to costs, profit and cash.
| Q3 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $296M | +14% | +8% |
| Gross profit | $197M | +20% | +4% |
| Operating profit | $94.0M | +49% | +68% |
| Net earnings | $45.5M | +94% | +210% |
| Operating cash flow | $81.2M | +155% | — |
| Free cash flow | $80.8M | +155% | — |
What changed
Revenue was $295.5M in Q3 FY25, up 8% year over year and up 14% from the previous quarter. Pen Needles was the largest line at 73% of revenue. Pen Needles added $15.6M year over year (up 8%), 68% of the total change. Other declined 9%.
Gross margin was 66.7%, down 3.1 points from a year earlier. Operating profit was $94.0M, a 31.8% margin (up 11.3 points year over year). Of the extra revenue versus a year earlier, 166% reached operating profit, above the 21% margin then. Operating expenses fell 23% while revenue rose 8%. Net earnings were $45.5M, up 210% year over year. The effective tax rate was 37.0%.
Operating cash flow was $81.2M, 178% of net earnings. Non-cash charges added back $9.2M of depreciation and amortization and $5.9M of share-based compensation. Working capital and other items added $20.6M. Capital expenditures of $400K left free cash flow of $80.8M.
Questions
What was Embecta's revenue in the third quarter fiscal 2025?
Embecta (EMBC) reported revenue of $296M for the third quarter fiscal 2025 (Q3 FY25), +8% from a year earlier and +14% from the quarter before.
Was Embecta profitable in the third quarter fiscal 2025?
Operating profit was $94.0M (31.8% of revenue) and net earnings $45.5M.
Source: Embecta 10-Q on SEC EDGAR.